ESR1 and breast carcinoma: Furthermore, the MCL1 inhibitor, S63845, could potentiate apoptosis when combined with a low dose of RMC-6272 (Supplementary Fig. 2C, D), suggesting that MCL1 loss is rate limiting at triggering apoptosis in ER+ breast cancer cells.